Lifeline arrives for world's top drug

Posted 2 April 2025 PM

MSD is closer to staving off a patent cliff for its highest earning blockbuster with the first data from a pivotal Phase 3 trial showing faster administration times for a similar efficacy.

Keytruda, the world's top selling drug, is subsidised for a growing list of indications and its PBS reimbursements are soaring, while global sales in the fourth quarter of last year grew 21 per cent to $12.4 billion (US$7.8 billion), around 12 per cent of MSD's total earnings. However, US patents are due to expire in 2028.

To see the whole article, please login